Epidemiology and characteristics of febrile neutropenia in oncology patients from Spanish tertiary care hospitals: PINNACLE study

• Published in: Molecular and clinical oncology Vol. 3; no. 3; pp. 725 - 729
• Main Authors: DE CASTRO CARPEÑO, JAVIER, GASCÓN-VILAPLANA, PERE, TEJERINA, ANA MARIA CASAS-FERNÁNDEZ-DE, ANTÓN-TORRES, ANTONIO, LÓPEZ-LÓPEZ, RAFAEL, BARNADAS-MOLINS, AGUSTÍ, CRUZ-HERNÁNDEZ, JUAN JESÚS, MASSUTI-SUREDA, BARTOMEU, CAMPS-HERRERO, CARLOS, ARANDA-AGUILAR, ENRIQUE, LASERNA, FRANCISCO JOSÉ REBOLLO
• Format: Journal Article
• Language: English
• Published: England D.A. Spandidos 01-05-2015; Spandidos Publications; Spandidos Publications UK Ltd
• Subjects: Antibiotics; Cancer; Chemotherapy; Complications and side effects; Epidemiology; febrile neutropenia; Fever; Granulocytes; Hospitalization; Mortality; Neutropenia; Neutrophils; Oncology; Patients; Penicillin; PINNACLE study; Quality of life; Risk factors; Spain; Spain; cancer; PINNACLE study; febrile neutropenia; hospitalization; chemotherapy; Spain
• ISSN: 2049-9450; 2049-9469
• DOI: 10.3892/mco.2015.524

Febrile neutropenia (FN) is one of the most common adverse events associated with myelosuppressive chemotherapy for cancer treatment. The objective of this study was to describe the incidence of hospitalization due to FN in Spanish tertiary care hospitals (PINNACLE study). This epidemiological, retrospective, multicenter, nationwide study involved 119 patients from oncology units of 10 Spanish tertiary care hospitals who were admitted for FN. The primary endpoint was to assess the epidemiology and characteristics of FN. The incidence of admissions due to FN in oncology patients was 2.0% (interquartile range [IQR], 1.6-3.0). In terms of fever and absolute neutrophil count (ANC), 37.0% of the patients had a temperature of ≥38.2°C and an ANC of ≤500/m3. The number of patients who received prophylactic treatment with granulocyte colony-stimulating factor (G-CSF) was significantly higher in the palliative group (32.6%) compared with that in the non-palliative group (13.5%). The hospital length of stay was significantly shorter in patients who received prophylactic G-CSF compared with those who did not (5.0 days; IQR, 4.0-9.0 vs. 7.0 days; IQR, 5.0-11.0, respectively). The hospital length of stay was also significantly shorter in patients receiving palliative treatment (5.0 days; IQR, 3.0-7.0) compared with those receiving non-palliative therapy (7.0 days; IQR, 5.0-12.0). In conclusion, the incidence of admissions due to FN in oncology patients was 2.0% and the duration of hospital stay was 7.0 days. Prophylactic G-CSF treatment was found to be associated with better outcomes and shorter hospital stays. Therefore, the use of this treatment becomes relevant for achieving better clinical outcomes and reducing hospitalization cost in the management of FN.